EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE 
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
At the recent European Haematology Association (EHA) Annual Congress 2018, Myeloma Patients Europe (MPE) and Video Journal of Hematological Oncology (VJHemOnc), filmed an interview with Dr Michael Hudecek (University of Würzburg, Germany) on the Horizon2020 CARAMBA project. The video was recorded in English and has now been translated into four additional languages: French, German, Spanish and Italian.
Daratumumab (Darzalex®), an immunotherapy drug for the treatment of myeloma, has been granted marketing authorisation (e.g. a licence) by the European Commission. It is specifically licensed for use in combination with bortezomib (Velcade®), melphalan and prednisolone (D-VMP) in newly diagnosed myeloma patients who are ineligible for high-dose therapy and autologous stem cell transplantation.
One of the challenges haematologists face in myeloma is how to treat frailer patients. Whilst the availability of proteasome inhibitors (PIs) (e.g. bortezomib [Velcade®], ixazomib [Ninlaro®] and carfilzomib [Kyprolis®]) and immunomodulatory agents (IMiDs) (e.g. thalidomide, lenalidomide [Revlimid®] and pomalidomide [Imnovid®]), have significantly improved the outcomes of myeloma patients in the last decade, frailer patients have shown a lesser improvement. This is mainly due to the toxicity some drugs can have in frailer patients, which may…
It is with great sadness that we inform you that our friend and colleague Wiesława Adamiec, President of Fundacja Carita (Poland), has passed away.
A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North America, according to the announcement the European Society of Medical Oncology (ESMO) has done today.
The contribution of patients and patient experts provides tangible value to other stakeholders and society that should be fairly compensated. Currently, there is no transparent and consistent system for financial compensation in place that reflects the level of individual contribution and expertise.
Daratumumab (Darzalex®), an immunotherapy drug for the treatment of myeloma, has received a positive recommendation by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).
At the recent European Haematology Association (EHA) Annual Congress 2018, Myeloma Patients Europe (MPE) and Video Journal of Hematological Oncology (VJHemOnc), filmed an interview with Dr Michael Hudecek (University of Würzburg, Germany) on the Horizon2020 CARAMBA project. MPE is collaborating with a consortium of European partners, including the University of Würzburg, on CARAMBA which is studying an innovative new treatment called chimeric antigen receptor T-cell (CAR-T) therapy in myeloma. In this video, Michael explains CAR-T…
The most important scientific meeting about haematological diseases in Europe, the European Haematology Association (EHA) Annual Meeting, took place in Stockholm from 14 to 17 June 2018. Immunotherapy, CAR-T cell therapy and drug combinations were some of the key topics presented.
